{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016253","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.019275+00:00","generated_at":"2026-06-24T01:30:49.323357+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TScan Q2 net loss $15.1M; cash $125.6M funds into 2024; TSC-101 IND cleared","bullets":["Net loss $15.1M vs $10.7M in prior-year quarter; revenue $4.1M (up from $2.8M) on Novartis collaboration.","Cash and equivalents $125.6M (plus $5M restricted); runway into 2024.","FDA cleared IND for TSC-101 (HA-2) for HCT relapse prevention; Phase 1 umbrella trial now enrolling.","Debora Barton, M.D., appointed Chief Medical Officer; brings cell therapy and oncology R&D experience.","Plans to file INDs for solid-tumor candidates TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016253","json":"https://secwatch.observer/filing/0000950170-22-016253.json","markdown":"https://secwatch.observer/filing/0000950170-22-016253.md","text":"https://secwatch.observer/filing/0000950170-22-016253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017022016253/0000950170-22-016253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017022016253/tcrx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:30:49.323357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}